At the news
? BULLISHIMPACT 7/10 8-K filed Jul 20, 2026 at 07:35 ET
Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review with a PDUFA target date of January 21, 2027. The company expects a potential U.S. launch in Q1 2027 if approved, marking a significant regulatory milestone for this clinical-stage biotech.
- FDA accepted BLA for z-rostudirsen (DYNE-251) for DMD exon 51 skipping
- Priority Review granted with PDUFA target action date of January 21, 2027
- Company expects potential U.S. launch in first quarter of 2027, assuming approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access